Literature DB >> 24120983

Laparoscopic reversal of Roux-en-Y gastric bypass: technique and utility for treatment of endocrine complications.

Guilherme M Campos1, Martynas Ziemelis2, Rodis Paparodis3, Muhammed Ahmed3, Dawn Belt Davis4.   

Abstract

BACKGROUND: The anatomic and physiologic changes with Roux-en-Y gastric bypass (RYGB) may lead to uncommon but occasionally difficult to treat complications such as hyperinsulinemic hypoglycemia with neuroglycopenia and recalcitrant hypocalcemia associated to hypoparathyroidism. Medical management of these complications is challenging. Laparoscopic reversal of RYGB anatomy with restoration of pyloric function and duodenal continuity is a potential treatment. The objective of this study was to present the indications, surgical technique, and clinical outcomes of laparoscopic reversal of RYGB.
METHODS: Prospective study of consecutive patients offered laparoscopic reversal of RYGB.
RESULTS: Five patients with remote laparoscopic RYGB underwent laparoscopic reversal of RYGB to normal anatomy (n = 2) or modified sleeve gastrectomy (n = 3). Indications were medically refractory hyperinsulinemic hypoglycemia with neuroglycopenia (n = 3), recalcitrant hypocalcemia with hypoparathyroidism (n = 1), and both conditions simultaneously (n = 1). Before reversal, all patients had a gastrostomy tube placed in the excluded stomach to document improvement of symptoms. Laparoscopic reversal was accomplished successfully in all patients. Three postoperative complications occurred: bleeding that required transfusion, gallstone pancreatitis, and a superficial trocar site infection. Average length of stay was 3 days. At a mean follow-up of 12 months (range 3 to 22), no additional episodes of neuroglycopenia occurred, average number of hypoglycemic episodes per week decreased from 18.5 ± 12.4 to 1.5 ± 1.9 (P = .05), and hypocalcemia became responsive to oral replacement therapy in both patients.
CONCLUSIONS: Laparoscopic reversal of RYGB to normal anatomy or modified sleeve gastrectomy is feasible and may be a therapeutic option for selected patients with medically refractory hyperinsulinemic hypoglycemia and/or recalcitrant hypocalcemia associated with hypoparathyroidism.
Copyright © 2014 American Society for Bariatric Surgery. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Bariatric surgery; GLP-1; Gastric bypass; Hyperinsulinemic hypoglycemia; Hypocalcemia; Hypoglycemia; Hypoparathyroidism; Laparoscopic reversal; Nesidioblastosis; Reversal; Sleeve gastrectomy

Mesh:

Year:  2013        PMID: 24120983      PMCID: PMC5947315          DOI: 10.1016/j.soard.2013.05.012

Source DB:  PubMed          Journal:  Surg Obes Relat Dis        ISSN: 1550-7289            Impact factor:   4.734


  35 in total

Review 1.  Management of complications following pancreatic resection: an evidence-based approach.

Authors:  James J Mezhir
Journal:  J Surg Oncol       Date:  2012-04-25       Impact factor: 3.454

Review 2.  The replication of beta cells in normal physiology, in disease and for therapy.

Authors:  Peter C Butler; Juris J Meier; Alexandra E Butler; Anil Bhushan
Journal:  Nat Clin Pract Endocrinol Metab       Date:  2007-11

3.  Profound hypocalcemia after near-total thyroidectomy in a Roux-en-Y gastric bypass patient.

Authors:  Eric M Salinger; John T Moore
Journal:  Am Surg       Date:  2010-04       Impact factor: 0.688

4.  Hyperinsulinemic hypoglycemia after gastric bypass surgery is not accompanied by islet hyperplasia or increased beta-cell turnover.

Authors:  Juris J Meier; Alexandra E Butler; Ryan Galasso; Peter C Butler
Journal:  Diabetes Care       Date:  2006-07       Impact factor: 19.112

5.  The role of dumping syndrome in weight loss after gastric bypass surgery.

Authors:  Ambar Banerjee; Yi Ding; Dean J Mikami; Bradley J Needleman
Journal:  Surg Endosc       Date:  2012-12-12       Impact factor: 4.584

6.  A multisite study of long-term remission and relapse of type 2 diabetes mellitus following gastric bypass.

Authors:  David E Arterburn; Andy Bogart; Nancy E Sherwood; Stephen Sidney; Karen J Coleman; Sebastien Haneuse; Patrick J O'Connor; Mary Kay Theis; Guilherme M Campos; David McCulloch; Joe Selby
Journal:  Obes Surg       Date:  2013-01       Impact factor: 4.129

7.  Hyperinsulinemic hypoglycemia with nesidioblastosis after gastric-bypass surgery.

Authors:  Geoffrey J Service; Geoffrey B Thompson; F John Service; James C Andrews; Maria L Collazo-Clavell; Ricardo V Lloyd
Journal:  N Engl J Med       Date:  2005-07-21       Impact factor: 91.245

8.  Effects of gastric bypass and gastric banding on glucose kinetics and gut hormone release.

Authors:  Frédérique Rodieux; Vittorio Giusti; David A D'Alessio; Michel Suter; Luc Tappy
Journal:  Obesity (Silver Spring)       Date:  2008-02       Impact factor: 5.002

9.  Postgastric bypass hyperinsulinemic hypoglycemia syndrome: characterization and response to a modified diet.

Authors:  Todd Andrew Kellogg; John P Bantle; Daniel B Leslie; James B Redmond; Bridget Slusarek; Therese Swan; Henry Buchwald; Sayeed Ikramuddin
Journal:  Surg Obes Relat Dis       Date:  2008 Jul-Aug       Impact factor: 4.734

10.  Pancreatic duct replication is increased with obesity and type 2 diabetes in humans.

Authors:  A E Butler; R Galasso; A Matveyenko; R A Rizza; S Dry; P C Butler
Journal:  Diabetologia       Date:  2009-10-21       Impact factor: 10.122

View more
  23 in total

1.  [Primary hyperparathyroidism after obesity surgery].

Authors:  K Lorenz; J Hein; H Dralle
Journal:  Chirurg       Date:  2014-12       Impact factor: 0.955

2.  Total pancreatectomy for the management of refractory post-gastric bypass hypoglycemia.

Authors:  Gaya Spolverato; Feriyl Bhaijee; Robert Anders; Kelsey Salley; Joan Parambi; Todd Brown; Timothy M Pawlik
Journal:  Dig Dis Sci       Date:  2014-10-26       Impact factor: 3.199

3.  Laparoscopic reversal of mini-gastric bypass to original anatomy for severe postoperative malnutrition.

Authors:  Laurent Genser; Antoine Soprani; Malek Tabbara; Jean-Michel Siksik; Jean Cady; Sergio Carandina
Journal:  Langenbecks Arch Surg       Date:  2017-08-12       Impact factor: 3.445

4.  Laparoscopic Revision of Bariatric Surgeries in Two Patients with Severe Resistant Hypocalcemia After Endocrine Cervical Surgery.

Authors:  Magda Zaarour; Ramona Zaharia; Marion Bretault; Christel Jublanc; Capucine De Marcellus; Jean-Luc Bouillot; Hervé Lefebvre; Jean-Michel Oppert; Judith Aron-Wisnewsky; Marie-Laure Raffin-Sanson
Journal:  Obes Surg       Date:  2020-04       Impact factor: 4.129

5.  One-Anastomosis Jejunal Interposition with Gastric Remnant Resection (Branco-Zorron Switch) for Severe Recurrent Hyperinsulinemic Hypoglycemia after Gastric Bypass for Morbid Obesity.

Authors:  Ricardo Zorron; Alcides Branco; Jose Sampaio; Claudia Bothe; Tido Junghans; Gyurdzhan Rasim; Johann Pratschke; Safak Guel-Klein
Journal:  Obes Surg       Date:  2017-04       Impact factor: 4.129

Review 6.  Revisional Bariatric/Metabolic Surgery: What Dictates Its Indications?

Authors:  Pearl Ma; Subhash Reddy; Kelvin D Higa
Journal:  Curr Atheroscler Rep       Date:  2016-07       Impact factor: 5.113

Review 7.  Surgical Treatment for Postprandial Hypoglycemia After Roux-en-Y Gastric Bypass: a Literature Review.

Authors:  Qiang Xu; Xi Zou; Lei You; Wenming Wu; Huijuan Zhu; Linjie Wang; Tao Yuan; Yupei Zhao
Journal:  Obes Surg       Date:  2021-02-01       Impact factor: 4.129

8.  Management of Excessive Weight Loss Following Laparoscopic Roux-en-Y Gastric Bypass: Clinical Algorithm and Surgical Techniques.

Authors:  Ikemefuna Akusoba; T Javier Birriel; Maher El Chaar
Journal:  Obes Surg       Date:  2016-01       Impact factor: 4.129

9.  Medium-Term Outcomes after Reversal of Roux-en-Y Gastric Bypass.

Authors:  Gustavo Andrés Arman; J Himpens; R Bolckmans; D Van Compernolle; R Vilallonga; G Leman
Journal:  Obes Surg       Date:  2018-03       Impact factor: 4.129

Review 10.  [Conversional and endoscopic procedures following bariatric surgery].

Authors:  R Zorron; C Bothe; T Junghans; J Pratschke; C Benzing; F Krenzien
Journal:  Chirurg       Date:  2016-10       Impact factor: 0.955

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.